Capstone Asset Management Co. Increases Position in Allergan PLC (AGN)
Capstone Asset Management Co. raised its position in shares of Allergan PLC (NYSE:AGN) by 8.8% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 16,560 shares of the company’s stock after buying an additional 1,345 shares during the period. Capstone Asset Management Co.’s holdings in Allergan PLC were worth $3,814,000 at the end of the most recent quarter.
A number of other large investors have also modified their holdings of AGN. Barnett & Company Inc. bought a new position in shares of Allergan PLC during the first quarter valued at $111,000. Boothbay Fund Management LLC acquired a new position in Allergan PLC during the first quarter valued at approximately $378,000. Kistler Tiffany Companies LLC raised its position in Allergan PLC by 2.2% in the second quarter. Kistler Tiffany Companies LLC now owns 920 shares of the company’s stock valued at $213,000 after buying an additional 20 shares during the last quarter. Integrated Investment Consultants LLC raised its position in Allergan PLC by 35.2% in the second quarter. Integrated Investment Consultants LLC now owns 592 shares of the company’s stock valued at $137,000 after buying an additional 154 shares during the last quarter. Finally, New England Research & Management Inc. acquired a new position in Allergan PLC during the second quarter valued at approximately $341,000. 86.89% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Allergan PLC (NYSE:AGN) traded up 1.39% during midday trading on Tuesday, reaching $192.64. 5,482,083 shares of the company’s stock traded hands. The stock’s 50 day moving average price is $211.32 and its 200 day moving average price is $233.30. Allergan PLC has a 52-week low of $184.50 and a 52-week high of $322.68. The firm has a market capitalization of $72.26 billion, a P/E ratio of 5.40 and a beta of 1.08.
Allergan PLC (NYSE:AGN) last released its quarterly earnings data on Wednesday, November 2nd. The company reported $3.32 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.65 by $0.33. The firm had revenue of $3.62 billion for the quarter, compared to the consensus estimate of $3.73 billion. Allergan PLC had a net margin of 93.74% and a return on equity of 7.26%. The business’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $3.48 earnings per share. On average, equities research analysts anticipate that Allergan PLC will post $13.37 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 28th. Stockholders of record on Tuesday, February 28th will be given a dividend of $0.70 per share. This is a boost from Allergan PLC’s previous quarterly dividend of $0.05. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.45%.
AGN has been the topic of several research reports. Vetr lowered shares of Allergan PLC from a “strong-buy” rating to a “buy” rating and set a $276.34 price target on the stock. in a report on Tuesday, August 2nd. JPMorgan Chase & Co. set a $325.00 price objective on shares of Allergan PLC and gave the company a “buy” rating in a research report on Friday, August 5th. Deutsche Bank AG lowered their price objective on shares of Allergan PLC from $282.00 to $278.00 and set a “buy” rating for the company in a research report on Tuesday, August 9th. Leerink Swann set a $294.00 price objective on shares of Allergan PLC and gave the company a “buy” rating in a research report on Monday, August 8th. Finally, Mizuho raised shares of Allergan PLC from a “neutral” rating to a “buy” rating and increased their price objective for the company from $248.00 to $318.00 in a research report on Friday, August 19th. Seven analysts have rated the stock with a hold rating and twenty have issued a buy rating to the stock. Allergan PLC presently has an average rating of “Buy” and an average target price of $289.11.
In related news, CFO Maria Teresa Hilado purchased 1,422 shares of the stock in a transaction on Friday, November 11th. The shares were purchased at an average cost of $210.64 per share, for a total transaction of $299,530.08. Following the completion of the transaction, the chief financial officer now directly owns 12,659 shares of the company’s stock, valued at approximately $2,666,491.76. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Brent L. Saunders purchased 5,250 shares of the stock in a transaction on Monday, November 21st. The stock was bought at an average price of $189.13 per share, for a total transaction of $992,932.50. The disclosure for this purchase can be found here. Insiders own 0.27% of the company’s stock.
Allergan PLC Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Stock Ratings for Allergan PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC and related stocks with our FREE daily email newsletter.